Can Merck Grow Without A Megamerger?
For a stock that was once an icon for investors and a company that's arguably the premier drug-discovery juggernaut, Merck isn't getting much respect. Drug stocks trade at almost 29 times 1999 earnings, but Merck & Co.'s price-earnings ratio is only about 26, even after a recent runup. The reason: Wall Street expects a big slowdown in Merck's growth rate after 2000 as a number of its drugs go off patent and lose a lot of sales to cheaper generic versions.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Ivanka Trump Faces Courtroom Showdown Over $785 Sandals
- Uber Losing Battle in London After Regulator Revokes License
- Mercedes Plots Tesla Attack With $1 Billion U.S. Electric Push
- How Electric Cars Can Create the Biggest Disruption Since the iPhone
- Hewlett Packard Enterprise Is Said to Plan About 5,000 Job Cuts